Medicine®

OPEN

The value of contrast-enhanced ultrasound in predicting postoperative recurrence of hepatocellular carcinoma
A protocol for systematic review and meta-analysis

Jieying Fu, MB[a], Jia Tang, MB[b], Huan Luo, MB[b], Wencui Wu, MB[c],* [iD]

Abstract

Background: As one of the key factors, postoperative recurrence of hepatocellular carcinoma (HCC) influences the therapeutic effects and survival period of patients. Therefore, the early diagnosis of postoperative recurrence of HCC plays an important role in improving the therapeutic effects and prognosis. Contrast-enhanced ultrasound (CEUS) plays an important role in the early diagnosis of postoperative recurrence of HCC. However, the accuracy of CEUS in predicting postoperative recurrence of HCC is still controversial. Therefore, in this study, a meta-analysis was carried out to further evaluate the accuracy of CEUS in predicting postoperative recurrence of HCC, thus providing evidence support for the early diagnosis of HCC.

Methods: The literatures on the CEUS diagnosis of postoperative recurrence of HCC were collected by searching China National Knowledge Infrastructure, Wanfang, China Biology Medicine disc, PubMed, EMBASE, Cochrane Library, and Web of Science on computer. The retrieval time is set from the start of the database until April 2021. The meta-analysis of the literatures that meet the quality standards was conducted by Stata 16.0 software.

Results: The results of this meta-analysis will be submitted to a peer-reviewed journal for publication.

Conclusion: This study will provide evidence support for the accuracy of CEUS in the diagnosis of postoperative recurrence of HCC.

Ethics and dissemination: The private information from individuals will not be published. This systematic review also should not damage participants' rights. Ethical approval is not available. The results may be published in a peer-reviewed journal or disseminated in relevant conferences.

OSF Registration Number: DOI 10.17605/OSF.IO/HB46W.

Abbreviations: CEUS = contrast-enhanced ultrasound, CT = computed tomography, HCC = hepatocellular carcinoma.

Keywords: contrast-enhanced ultrasound, diagnosis, hepatocellular carcinoma, meta-analysis, protocol, recurrence

1. Introduction

Hepatocellular carcinoma (HCC) is one of the most common cancers in China.[1,2] According to reports, the mortality rate ranks the third among malignant tumors in digestive system.[3] In recent years, with the development of economy and the change of people's living habits, the incidence and mortality of the disease are increasing year by year. Postoperative recurrence of HCC is one of the key factors affecting the therapeutic effects and survival period of patients.[4] Therefore, the early diagnosis of postoperative recurrence of HCC plays an important role in improving the therapeutic effects and prognosis.

At present, the clinical methods adopted to determine the recurrence of HCC include AFP detection and imaging examination.[5,6] The former is simple to be operated and is widely used in clinic, with high value in the diagnosis of HCC.[7] The latter includes ordinary ultrasound, contrast-enhanced ultrasound (CEUS), computed tomography (CT), magnetic resonance imaging, and so on.[8–10] In recent years, with the continuous improvement of CEUS technology and the application of ultrasound contrast agent, it displays more and more

obvious advantages in the diagnosis of liver space-occupying lesions.[11]

The diagnostic performance of CEUS for postoperative recurrence of HCC has been continuously evaluated and confirmed as well. However, there exist inconsistencies in the effects in various literatures.[12–18] The purpose of this study is to perform meta-analysis to explore the value of CEUS in predicting the postoperative recurrence of HCC, thus providing reference basis for early clinical diagnosis.

2. Methods

2.1. Study registration

The protocol of the systematic review has been registered on Open Science Framework (registration number: DOI 10.17605/OSF.IO/HB46W). It was reported by following the guideline of preferred reporting items for systematic reviews and meta-analysis protocol statement.[19]

2.2. Inclusion criteria for study selection

Inclusion criteria:

(1) To explore the diagnostic value of CEUS in the diagnosis of postoperative recurrence of HCC.
(2) All patients who accepted the operation of HCC were included.
(3) The gold standard was clinicopathological diagnosis, comprehensive imaging examination (enhanced CT, magnetic resonance imaging), and long-term clinical follow-up results.
(4) The data of the 4 tables of diagnostic tests can be obtained directly or indirectly.

Exclusion criteria:

(1) Literatures with incorrect data sources, incomplete data, and incorrect statistical methods.
(2) Literatures with repeated research data.
(3) Case reports, reviews, cell, or animal studies.

2.3. Data sources and search strategy

This study conducted a literature search in the China National Knowledge Infrastructure, Wanfang, China Biology Medicine disc, PubMed, EMBASE, Cochrane Library, and Web of Science. The retrieval time is set from the build of the database until April 2021. The language restrictions are Chinese and English. The search strategy for PubMed is displayed in Table 1.

2.4. Data collection and analysis

2.4.1. Study selection. All literatures were screened independently by 2 researchers based on the inclusion and exclusion criteria. In case of disagreement, a decision is made through discussion or consultation with relevant experts. The screening flow chart of this study is demonstrated in Figure 1.

2.4.2. Data extraction. The following information was extracted: first author, year of publication, type of study, language, sample size, average age, gold standard, as well as true positive, false positive, true negative, and false negative. When the data collected by the 2 researchers are inappropriate, an agreement is reached through consultation. If the disagreement still exists after consultation, a third party (not the researcher) should be asked to make a decision.

Table 1

PubMed search strategy.

Number	Search terms
#1	Carcinoma, Hepatocellular[MeSH]
#2	Hepatocellular Carcinoma[Title/Abstract]
#3	Hepatoma[Title/Abstract]
#4	Liver Cancer, Adult[Title/Abstract]
#5	Liver Cell Carcinoma[Title/Abstract]
#6	Liver Cell Carcinoma, Adult[Title/Abstract]
#7	Adult Liver Cancer[Title/Abstract]
#8	Adult Liver Cancers[Title/Abstract]
#9	Cancer, Adult Liver[Title/Abstract]
#10	Cancers, Adult Liver[Title/Abstract]
#11	Carcinoma, Liver Cell[Title/Abstract]
#12	Carcinomas, Hepatocellular[Title/Abstract]
#13	Carcinomas, Liver Cell[Title/Abstract]
#14	Cell Carcinoma, Liver[Title/Abstract]
#15	Cell Carcinomas, Liver[Title/Abstract]
#16	Hepatocellular Carcinomas[Title/Abstract]
#17	Hepatomas[Title/Abstract]
#18	Liver Cancers, Adult[Title/Abstract]
#19	Liver Cell Carcinomas[Title/Abstract]
#20	or/1-19
#21	Recurrence[MeSH]
#22	Recrudescence[Title/Abstract]
#23	Relapse[Title/Abstract]
#24	Recrudescences[Title/Abstract]
#25	Recurrences[Title/Abstract]
#26	Relapses[Title/Abstract]
#27	Neoplasm Recurrence, Local[MeSH]
#28	Local Neoplasm Recurrence[Title/Abstract]
#29	Local Neoplasm Recurrences[Title/Abstract]
#30	Locoregional Neoplasm Recurrence[Title/Abstract]
#31	Neoplasm Recurrence, Locoregional[Title/Abstract]
#32	Neoplasm Recurrences, Local[Title/Abstract]
#33	Recurrence, Local Neoplasm[Title/Abstract]
#34	Recurrence, Locoregional Neoplasm[Title/Abstract]
#35	Recurrences, Local Neoplasm[Title/Abstract]
#36	Locoregional Neoplasm Recurrences[Title/Abstract]
#37	Neoplasm Recurrences, Locoregional[Title/Abstract]
#38	Recurrences, Locoregional Neoplasm[Title/Abstract]
#39	or/21-38
#40	Contrast-enhanced ultrasound[Title/Abstract]
#41	CEUS[Title/Abstract]
#42	or/40-41
#43	Diagnos*[Title/Abstract]
#44	Sensitivity[Title/Abstract]
#45	Specificity[Title/Abstract]
#46	ROC curve[Title/Abstract]
#47	or/43-46
#48	#20 and #39 and #42 and #47

2.4.3. Dealing with missing data. If there are insufficient or missing data in the literature, the authors will be contacted via email. If the data are still not available, only the current available data will be analyzed and the potential impacts will be discussed.

2.5. Quality assessment

The methodological quality of the included studies was assessed by following quality assessment of diagnostic accuracy studies-2 criteria,[20] including 11 evaluation criteria. Each standard is evaluated by "yes," "no," and "unclear." "Yes" refers to that it meets this standard, "No" means that it does not meet this

Figure 1. Flow diagram of literature retrieval.

standard or is not mentioned, and "unclear" is partially consistent or unable to obtain sufficient information for evaluation. If the 11 standards are met, the quality of the literature will be rated as "A;" if more than 1 item is "unclear," it will be rated as "B;" if "no" occurs, it will be rated as "C."

2.6. Statistical analysis

All of the above statistical analyses were performed with Stata 16.0 (StataCorp LLC, college station, TX). We calculated pooled sensitivity (SEN), specificity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio, area under the curve, and their 95% confidence interval. What's more, the pooled diagnostic value of CEUS through the summary receiver operating characteristic curve, and area under the curve was tested. The threshold effects were detected by applying spearman correlation coefficient. The calculation of heterogeneity was caused by the nonthreshold effects of Cochrane-Q and I^2 values. Meanwhile, a fixed effect model (without obvious inhomogeneity) or a random effect model (with significant heterogeneity) was employed to merge the data. The statistical test level was $\alpha = 0.05$.

2.7. Subgroup analysis

A subgroup analysis will be made on the basis of gold standard type, study type, surgery type, and threshold.

2.8. SEN analysis

We will adopt the one-by-one exclusion method to analyze the SEN of the results.

2.9. Reporting bias

The publication bias was determined by conducting Deeks' funnel plot asymmetry test.

2.10. Ethics and dissemination

Since the program does not include the recruitment of patients and the collection of personal information, it does not require the approval of the Ethics Committee.

3. Discussion

The postoperative recurrence of HCC is high.[21] At present, ultrasound and enhanced CT are routinely used for regular

follow-up. CEUS technology is also applied more and more widely. The neovascularization of recurrent and metastatic foci after HCC is abundant, and it is mainly supplied by hepatic artery.[22] When the contrast medium reached the hepatic artery, the lesion developed immediately, the intensity was higher than that of the surrounding normal liver tissue, homogeneity or inhomogeneity is enhanced, and the portal vein phase disappeared rapidly. Under the background of liver cirrhosis, CEUS can judge HCC and atypical hyperplastic nodules by contrast-enhanced imaging,[23] because CEUS can observe every moment from the development of the hepatic artery to the complete disappearance of the contrast medium. Furthermore, liver can be completely scanned in the portal phase and delayed phase, and it is easier to detect small lesions in liver.[24] With high SEN and accuracy, CEUS can be considered as a reliable method for follow-up after HCC. Many studies have confirmed that CEUS is of great value in predicting the recurrence after HCC. We performed a meta-analysis to determine the accuracy of CEUS in the prediction of the postoperative recurrence of HCC, so as to resolve the dispute.

Author contributions

Conceptualization: Wencui Wu, Jieying Fu.
Data collection: Jia Tang.
Funding acquisition: Wencui Wu.
Investigation: Wencui Wu.
Methodology: Huan Luo.
Project administration: Wencui Wu.
Resources: Huan Luo, Jia Tang.
Software: Jia Tang, Huan Luo.
Supervision: Wencui Wu, Jia Tang.
Validation: Jia Tang.
Visualization: Jia Tang.
Writing – original draft: Wencui Wu, Jieying Fu.
Writing – review & editing: Wencui Wu, Jieying Fu.

References

[1] Liu L, Qin S, Zhang Y. The evolving landscape of checkpoint inhibitor combination therapy in the treatment of advanced hepatocellular carcinoma. Target Oncol 2021;16:153–63.

[2] Cui K, Ou Y, Shen Y, Li S, Sun Z. Clinical value of circulating tumor cells for the diagnosis and prognosis of hepatocellular carcinoma (HCC): a systematic review and meta-analysis. Medicine 2020;99:e22242.

[3] Calvisi DF. Inhibition of hepatitis B virus-associated liver cancer by antiplatelet therapy: a revolution in hepatocellular carcinoma prevention? Hepatology 2013;57:848–50.

[4] He YZ, He K, Huang RQ, et al. A clinical scoring system for predicting tumor recurrence after percutaneous radiofrequency ablation for 3 cm or less hepatocellular carcinoma. Sci Rep 2021;11:8275.

[5] Wang Y, Shen Z, Zhu Z, Han R, Huai M. Clinical values of AFP, GPC3 mRNA in peripheral blood for prediction of hepatocellular carcinoma recurrence following OLT. Hepat Mon 2011;11:195–9.

[6] Ghanaati H, Alavian SM, Firouznia K, Abedini MR, Ataee R. Tailoring of interventional procedures for HCC patients-review article. Iran J Radiol 2011;7:129–43.

[7] Moudgil S, Kalra N, Prabhakar N, et al. Comparison of contrast enhanced ultrasound with contrast enhanced computed tomography for the diagnosis of hepatocellular carcinoma. J Clin Exp Hepatol 2017; 7:222–9.

[8] Schwarze V, Marschner C, Völckers W, et al. Diagnostic value of contrast-enhanced ultrasound versus computed tomography for hepatocellular carcinoma: a retrospective, single-center evaluation of 234 patients. J Int Med Res 2020;48:300060520930151.

[9] Ooi CC, Low SC, Schneider-Kolsky M, et al. Diagnostic accuracy of contrast-enhanced ultrasound in differentiating benign and malignant focal liver lesions: a retrospective study. J Med Imaging Radiat Oncol 2010;54:421–30.

[10] Sporea I, Badea R, Popescu A, et al. Contrast-enhanced ultrasound (CEUS) for the evaluation of focal liver lesions - a prospective multicenter study of its usefulness in clinical practice. Ultraschall Med 2014;35: 259–66.

[11] Liu D, Liu F, Xie X, et al. Accurate prediction of responses to transarterial chemoembolization for patients with hepatocellular carcinoma by using artificial intelligence in contrast-enhanced ultrasound. Eur Radiol 2020;30:2365–76.

[12] Gao Y, Zheng DY, Cui Z, Ma Y, Liu YZ, Zhang W. Predictive value of quantitative contrast-enhanced ultrasound in hepatocellular carcinoma recurrence after ablation. World J Gastroenterol 2015;21:10418–26.

[13] Wang Y, Liao J, Qi W, Xie L, Li Y. Predictive value of conventional ultrasound and contrast-enhanced ultrasound in early recurrence of hepatocellular carcinoma after surgical resection. Ultrasound Med Biol 2016;42:1042–8.

[14] Liu LF, Ding ZL, Zhong JH, et al. Contrast-enhanced ultrasound to monitor early recurrence of primary hepatocellular carcinoma after curative treatment. BioMed Res Int 2018;2018:8910562.

[15] Xiachuan Q, Xiang Z, Xuebing L, Yan L. Predictive value of contrast-enhanced ultrasound for early recurrence of single lesion hepatocellular carcinoma after curative resection. Ultrason Imaging 2019;41:49–58.

[16] Han X, Dong J, Liu Z, et al. Quantitative dynamic contrast-enhanced ultrasound to predict intrahepatic recurrence of hepatocellular carcinoma after radiofrequency ablation: a cohort study. Int J Hyperthermia 2020;37:1066–73.

[17] Ma QP, He XL, Li K, et al. Dynamic contrast-enhanced ultrasound radiomics for hepatocellular carcinoma recurrence prediction after thermal ablation. Mol Imaging Biol 2021;Epub ahead of print.

[18] Wang XY, Chen D, Zhang XS, Chen JF, Hu AB. Value of ^{18}F-FDG-PET/ CT in the detection of recurrent hepatocellular carcinoma after hepatectomy or radiofrequency ablation: a comparative study with contrast-enhanced ultrasound. J Dig Dis 2013;14:433–8.

[19] Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;350:g7647.

[20] Whiting PF, Rutjes AWS, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2019;155:529–36.

[21] Wang YK, Bi XY, Li ZY, et al. A new prognostic score system of hepatocellular carcinoma following hepatectomy. Zhonghua Zhong Liu Za Zhi 2017;39:903–9.

[22] Yan T, Zhao JJ, Bi XY, et al. Prognosis of hepatocellular carcinoma: a study of 832 cases. Zhonghua Zhong Liu Za Zhi 2013; 35:54–8.

[23] Gadiparthi C, Ali B, Cholankeril R, Nair S. Futility of ultrasonography as a screening tool for HCC in patients waitlisted for liver transplant. Is it time to revisit screening guidelines for hepatocellular carcinoma? Gastroenterology 2017;152:S1183–4.

[24] Kim HA, Kim KA, Choi JI, et al. Comparison of biannual ultrasonography and annual non-contrast liver magnetic resonance imaging as surveillance tools for hepatocellular carcinoma in patients with liver cirrhosis (MAGNUS-HCC): a study protocol. BMC cancer 2017;17:877.